Literature DB >> 32514928

Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera.

Ivan Krečak1, Hrvoje Holik2,3, Morić Perić Martina4, Ivan Zekanović4, Božena Coha2, Velka Gverić-Krečak5.   

Abstract

Chronic kidney disease (CKD) is a well-known risk factor for venous thromboembolism and cardiovascular (CV) disease development in the general population, but its role in thrombotic risk in essential thrombocythemia (ET) and polycythemia vera (PV) remains poorly understood. This retrospective multicenter study analyzed clinical correlations and the potential impact of CKD on thrombosis development in ET and PV patients. We included 167 patients (76 ET and 91 PV); 25.7% had CKD at diagnosis, defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 for ≥ 3 months. Lower eGFR correlated with advanced age, female sex, higher granulocytes, higher serum C-reactive protein, history of thrombosis, CV risk factors, and the presence of palpable splenomegaly. CKD was univariately associated with inferior thrombosis-free survival in the entire cohort, as well as in both ET and PV patients. These results remained significant in the multivariate Cox regression models when adjusted to disease-specific risk models. Therefore, CKD could be a risk factor for thrombosis in ET and PV patients. Additional studies on a larger number of patients are needed to confirm our findings and to elucidate whether the addition of CKD to the current risk stratification models might improve prognostication in ET and PV patients.

Entities:  

Keywords:  Chronic kidney disease; Essential thrombocythemia; Polycythemia vera; Survival; Thrombosis

Year:  2020        PMID: 32514928     DOI: 10.1007/s12185-020-02898-7

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  4 in total

1.  Beneficial effect of ACE inhibitors on kidney function in polycythemia vera.

Authors:  Ivan Krečak; Martina Morić Perić; Ivan Zekanović; Hrvoje Holik; Božena Coha; Velka Gverić-Krečak; Marko Lucijanić
Journal:  Wien Klin Wochenschr       Date:  2021-02-08       Impact factor: 1.704

2.  The Prevalence of Simple Kidney Cysts in Polycythemia Vera and Its Clinical Associations.

Authors:  Ivan Krečak; Hrvoje Holik; Marko Lucijanić
Journal:  Indian J Hematol Blood Transfus       Date:  2022-01-04       Impact factor: 0.900

Review 3.  Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia.

Authors:  Ivan Krecak; Marko Lucijanic; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2022-08-06       Impact factor: 4.213

4.  Higher serum uric acid is associated with higher risks of thrombosis and death in patients with primary myelofibrosis.

Authors:  Marko Lucijanic; Ivan Krecak; Davor Galusic; Martina Sedinic; Hrvoje Holik; Vlatka Perisa; Martina Moric Peric; Ivan Zekanovic; Tajana Stoos-Veic; Vlatko Pejsa; Rajko Kusec
Journal:  Wien Klin Wochenschr       Date:  2021-01-19       Impact factor: 1.704

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.